Silas Inman

The FDA has granted a priority review designation to cabozantinib as a treatment for patients with advanced renal cell carcinoma following progression on one prior therapy.

Nivolumab has improved overall survival versus investigator's choice of therapy for patients with platinum-refractory squamous cell carcinoma of the head and neck in the phase III CheckMate-141 trial.

The FDA has approved eribulin mesylate as a treatment for patients with advanced or unresectable liposarcoma following prior treatment with an anthracycline-based chemotherapy.

Adding panitumumab (Vectibix) to best supportive care reduced the risk of death by 30% for patients with RAS wild-type chemorefractory metastatic colorectal cancer.

The PD-1 inhibitor pembrolizumab (Keytruda) elicited encouraging activity with mild adverse events as a treatment for patients with advanced PD-L1–positive esophageal carcinoma.

Adding liposomal irinotecan to 5-fluorouracil and leucovorin reduced the risk of death by 25% for patients with metastatic pancreatic cancer following progression on a gemcitabine-based regimen.

Preoperative treatment with short-course radiation therapy plus 3 cycles of chemotherapy improved overall survival (OS) and was associated with fewer adverse events compared with standard chemoradiation for patients with locally advanced rectal cancer.

The FDA has granted a priority review designation to the combination of lenvatinib and everolimus as a treatment for patients with metastatic renal cell carcinoma following one prior VEGF-targeted therapy.

Regulatory filings have been submitted in the United States and Europe for the combination of lenvatinib and everolimus as a treatment for patients with metastatic renal cell carcinoma following a VEGF-targeted therapy.

The optimal frontline treatment strategy for patients with metastatic renal cell carcinoma could look dramatically different in the next few years, as studies assess combination strategies and predictive biomarkers for immunotherapy and targeted therapies.

Hypofractionated radiotherapy demonstrated similar toxicity and was noninferior to standard radiation therapy for preventing PSA increases or disease recurrences for men with intermediate-risk prostate cancer.

The addition of the CTLA-4 inhibitor ipilimumab to cisplatin and gemcitabine did not significantly improve overall survival for patients with metastatic urothelial cancer.

The FDA has approved a non-alcohol formulation of docetaxel as a treatment for patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

A new drug application has been submitted for cabozantinib as a treatment for patients with advanced renal cell carcinoma who have received one prior therapy.

Grade 3 diarrhea occurred in 16% of patients treated with neratinib and prophylactic loperamide, representing a significant reduction compared with phase III findings from the ExteNET trial.

The FDA has granted a breakthrough therapy designation to the third-generation EGFR TKI BI-1482694 as a potential treatment for patients with EGFR T790M-positive non–small cell lung cancer.

Frontline treatment with afatinib reduced the risk of progression or death by 27% compared with gefitinib for patients with EGFR-mutant non–small cell lung cancer.

Treatment with pembrolizumab reduced the risk of death by 29% compared with docetaxel for patients with PD-L1-positive non–small cell lung cancer.

Multimodal screening using CA-125 and a risk assessment algorithm could reduce the risk of mortality from ovarian cancer in certain women.

The European Commission has approved talimogene laherparepvec as a treatment for adult patients with unresectable stage IIIb, IIIc, and IVM1a melanoma that has not spread to the bone, brain, lung, or other viscera.

The MEK inhibitor binimetinib has demonstrated an improvement in progression-free survival compared with dacarbazine in patients with advanced NRAS-mutant melanoma.

The FDA has extended the review period for rociletinib in patients with EGFR T790M-positive non–small cell lung cancer by 3 months, to allow ample time to review additional data.

The oral pan-HER TKI neratinib continued to show similar rates of disease-free survival for patients with HER2-positive early-stage breast cancer at a 3-year analysis of the phase III ExteNET trial.

The FDA has granted an accelerated approval to alectinib as a treatment for patients with metastatic ALK-positive non–small cell lung cancer following progression on crizotinib.

Treatment with the PI3K inhibitor buparlisib plus fulvestrant showed a 1.9-month extension in progression-free survival compared with fulvestrant alone in women with endocrine-resistant HR-positive/HER2-negative advanced breast cancer.

The enzyme APOBEC3B has been associated with resistance to treatment with tamoxifen in retrospective studies and xenograft models of ER-positive breast cancer.

Frontline treatment with the PD-L1 inhibitor atezolizumab combined with nab-paclitaxel showed a confirmed objective response rate of 66.7% in patients with metastatic triple-negative breast cancer.

Prophylactic administration of standard heart failure medications helped preserve left ventricular ejection fraction in patients treated with trastuzumab for HER2-positive metastatic breast cancer.

Treatment with the PD-L1 inhibitor avelumab demonstrated promising overall response rates for patients with PD-L1–positive metastatic breast cancer, particularly for those with triple-negative disease.

Adding capecitabine to adjuvant therapy reduced the risk of disease recurrence by 30% and prolonged survival by 40% for patients with residual breast cancer following neoadjuvant chemotherapy and surgery.